Hypertension and diabetes are affected by the use of calcineurin inhibitors (CNI) and corticosteroids (STR), while dyslipidemia is affected by the use of CNI, STR, and mammalian target of rapamycin (mTOR) inhibitor (Elezaby et al., 2022). This evidence concerns the gene MTOR and Hypertension.